• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

免疫表型可预测多形性胶质母细胞瘤患者的生存率。

Immune phenotypes predict survival in patients with glioblastoma multiforme.

作者信息

Mostafa Haouraa, Pala Andrej, Högel Josef, Hlavac Michal, Dietrich Elvira, Westhoff M Andrew, Nonnenmacher Lisa, Burster Timo, Georgieff Michael, Wirtz C Rainer, Schneider E Marion

机构信息

Sektion Experimentelle Anaesthesiologie, University Hospital Ulm, Albert Einstein Allee 23, 89081, Ulm, Germany.

Klinik für Anaesthesiologie, University Hospital Ulm, Albert Einstein Allee 23, 89081, Ulm, Germany.

出版信息

J Hematol Oncol. 2016 Sep 1;9(1):77. doi: 10.1186/s13045-016-0272-3.

DOI:10.1186/s13045-016-0272-3
PMID:27585656
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5009501/
Abstract

BACKGROUND

Glioblastoma multiforme (GBM), a common primary malignant brain tumor, rarely disseminates beyond the central nervous system and has a very bad prognosis. The current study aimed at the analysis of immunological control in individual patients with GBM.

METHODS

Immune phenotypes and plasma biomarkers of GBM patients were determined at the time of diagnosis using flow cytometry and ELISA, respectively.

RESULTS

Using descriptive statistics, we found that immune anomalies were distinct in individual patients. Defined marker profiles proved highly relevant for survival. A remarkable relation between activated NK cells and improved survival in GBM patients was in contrast to increased CD39 and IL-10 in patients with a detrimental course and very short survival. Recursive partitioning analysis (RPA) and Cox proportional hazards models substantiated the relevance of absolute numbers of CD8 cells and low numbers of CD39 cells for better survival.

CONCLUSIONS

Defined alterations of the immune system may guide the course of disease in patients with GBM and may be prognostically valuable for longitudinal studies or can be applied for immune intervention.

摘要

背景

多形性胶质母细胞瘤（GBM）是一种常见的原发性恶性脑肿瘤，很少扩散至中枢神经系统以外，预后很差。本研究旨在分析GBM个体患者的免疫调控情况。

方法

分别在诊断时使用流式细胞术和酶联免疫吸附测定法确定GBM患者的免疫表型和血浆生物标志物。

结果

通过描述性统计，我们发现个体患者存在明显的免疫异常。特定的标志物谱对生存具有高度相关性。GBM患者中活化自然杀伤细胞与生存改善之间的显著关系，与病情恶化且生存期很短的患者中CD39和白细胞介素-10增加形成对比。递归分割分析（RPA）和Cox比例风险模型证实了CD8细胞绝对数量和低数量CD39细胞与更好生存的相关性。

结论

免疫系统的特定改变可能指导GBM患者的疾病进程，对于纵向研究可能具有预后价值，或者可用于免疫干预。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7048/5009501/9f79ec049939/13045_2016_272_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7048/5009501/9c8211c244ec/13045_2016_272_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7048/5009501/6a5e8fb03aa5/13045_2016_272_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7048/5009501/3e3b82bdce87/13045_2016_272_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7048/5009501/865e1561f00b/13045_2016_272_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7048/5009501/fa17bfd14c09/13045_2016_272_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7048/5009501/9f79ec049939/13045_2016_272_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7048/5009501/9c8211c244ec/13045_2016_272_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7048/5009501/6a5e8fb03aa5/13045_2016_272_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7048/5009501/3e3b82bdce87/13045_2016_272_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7048/5009501/865e1561f00b/13045_2016_272_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7048/5009501/fa17bfd14c09/13045_2016_272_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7048/5009501/9f79ec049939/13045_2016_272_Fig6_HTML.jpg

相似文献

1
Immune phenotypes predict survival in patients with glioblastoma multiforme.免疫表型可预测多形性胶质母细胞瘤患者的生存率。
J Hematol Oncol. 2016 Sep 1;9(1):77. doi: 10.1186/s13045-016-0272-3.
2
Role of adjuvant or salvage radiosurgery in the management of unresected residual or progressive glioblastoma multiforme in the pre-bevacizumab era.在贝伐单抗时代之前，辅助性或挽救性放射外科手术在多形性胶质母细胞瘤未切除的残留或进展病例管理中的作用。
J Neurosurg. 2015 Apr;122(4):757-65. doi: 10.3171/2014.11.JNS13295. Epub 2015 Jan 16.
3
Surrogate markers predict angiogenic potential and survival in patients with glioblastoma multiforme.替代标志物可预测多形性胶质母细胞瘤患者的血管生成潜力和生存期。
Neurosurgery. 2009 May;64(5):819-26; discussion 826-7. doi: 10.1227/01.NEU.0000343742.06625.DB.
4
Long-term outcome of patients with WHO Grade III and IV gliomas treated by fractionated intracavitary radioimmunotherapy.采用分次腔内放射免疫疗法治疗的世界卫生组织III级和IV级神经胶质瘤患者的长期预后。
J Neurosurg. 2015 Sep;123(3):760-70. doi: 10.3171/2014.12.JNS142168. Epub 2015 Jul 3.
5
Can MRI-derived factors predict the survival in glioblastoma patients treated with postoperative chemoradiation therapy?磁共振成像衍生因素能否预测胶质母细胞瘤患者术后放化疗后的生存率？
Acta Radiol. 2013 Mar 1;54(2):214-20. doi: 10.1258/ar.2012.120525. Epub 2012 Nov 8.
6
Chromosome 1p and 19q deletions in glioblastoma multiforme.多形性胶质母细胞瘤中的1号染色体短臂和19号染色体长臂缺失
Appl Immunohistochem Mol Morphol. 2009 Dec;17(6):512-6. doi: 10.1097/PAI.0b013e3181a2c6a4.
7
Influence of insurance status on survival of adults with glioblastoma multiforme: A population-based study.保险状况对多形性胶质母细胞瘤成人患者生存的影响：一项基于人群的研究。
Cancer. 2016 Oct 15;122(20):3157-3165. doi: 10.1002/cncr.30160. Epub 2016 Aug 8.
8
Diagnostic and prognostic value of glycosyltransferase mRNA in glioblastoma multiforme patients.糖基转移酶mRNA在多形性胶质母细胞瘤患者中的诊断和预后价值
Neuropathol Appl Neurobiol. 2006 Aug;32(4):410-8. doi: 10.1111/j.1365-2990.2006.00742.x.
9
A quantitative study of shape descriptors from glioblastoma multiforme phenotypes for predicting survival outcome.一项关于多形性胶质母细胞瘤表型形状描述符预测生存结果的定量研究。
Br J Radiol. 2016 Dec;89(1068):20160575. doi: 10.1259/bjr.20160575. Epub 2016 Oct 26.
10
Prognostic relevance of NG2/CSPG4, CD44 and Ki-67 in patients with glioblastoma.NG2/CSPG4、CD44和Ki-67在胶质母细胞瘤患者中的预后相关性
Tumour Biol. 2017 Sep;39(9):1010428317724282. doi: 10.1177/1010428317724282.

引用本文的文献

1
Unleashing NK cells for cancer immunotherapy in lung cancer: biologic challenges and clinical advances.释放自然杀伤细胞用于肺癌的癌症免疫治疗：生物学挑战与临床进展
J Exp Clin Cancer Res. 2025 Aug 23;44(1):251. doi: 10.1186/s13046-025-03503-7.
2
RIPK1 in Diffuse Glioma Pathology: From Prognosis Marker to Potential Therapeutic Target.RIPK1在弥漫性胶质瘤病理学中的作用：从预后标志物到潜在治疗靶点
Int J Mol Sci. 2025 Jun 10;26(12):5555. doi: 10.3390/ijms26125555.
3
CENPF interaction with PLA2G4A promotes glioma growth by modulating mTORC1 and NF-κB pathways.

本文引用的文献

1
Isocitrate Dehydrogenase (IDH)1/2 Mutations as Prognostic Markers in Patients With Glioblastomas.异柠檬酸脱氢酶（IDH）1/2突变作为胶质母细胞瘤患者的预后标志物
Medicine (Baltimore). 2016 Mar;95(9):e2583. doi: 10.1097/MD.0000000000002583.
2
Tumor-associated macrophages in glioblastoma multiforme-a suitable target for somatostatin receptor-based imaging and therapy?多形性胶质母细胞瘤中的肿瘤相关巨噬细胞——基于生长抑素受体的成像和治疗的合适靶点？
PLoS One. 2015 Mar 25;10(3):e0122269. doi: 10.1371/journal.pone.0122269. eCollection 2015.
3
Epigenetic and transcriptional control of Foxp3+ regulatory T cells.
CENPF与PLA2G4A的相互作用通过调节mTORC1和NF-κB信号通路促进胶质瘤生长。
Cancer Cell Int. 2025 Mar 1;25(1):73. doi: 10.1186/s12935-025-03700-6.
4
Identification of inflammation-related genes signature to establish a prognostic model in MGMT unmethylated glioblastoma patients.鉴定炎症相关基因特征以建立O6-甲基鸟嘌呤-DNA甲基转移酶未甲基化胶质母细胞瘤患者的预后模型。
Discov Oncol. 2025 Feb 11;16(1):154. doi: 10.1007/s12672-025-01894-9.
5
Research Progress of NK Cells in Glioblastoma Treatment.自然杀伤细胞在胶质母细胞瘤治疗中的研究进展
Onco Targets Ther. 2025 Jan 18;18:87-106. doi: 10.2147/OTT.S486411. eCollection 2025.
6
Prospective Molecular Targets for Natural Killer Cell Immunotherapy against Glioblastoma Multiforme.针对多形性胶质母细胞瘤的自然杀伤细胞免疫治疗的潜在分子靶点。
Cells. 2024 Sep 17;13(18):1567. doi: 10.3390/cells13181567.
7
Pathophysiological role of histamine signaling and its implications in glioblastoma.组蛋白信号在胶质母细胞瘤中的病理生理学作用及其意义。
Biochim Biophys Acta Rev Cancer. 2024 Sep;1879(5):189146. doi: 10.1016/j.bbcan.2024.189146. Epub 2024 Jun 30.
8
A longer time to relapse is associated with a larger increase in differences between paired primary and recurrent IDH wild-type glioblastomas at both the transcriptomic and genomic levels.复发时间延长与配对的原发性和复发性 IDH 野生型胶质母细胞瘤在转录组和基因组水平上的差异增加幅度更大相关。
Acta Neuropathol Commun. 2024 May 18;12(1):77. doi: 10.1186/s40478-024-01790-3.
9
Pan-cancer analysis implicates novel insights of lactate metabolism into immunotherapy response prediction and survival prognostication.泛癌症分析提示了乳酸代谢在免疫治疗反应预测和生存预后中的新见解。
J Exp Clin Cancer Res. 2024 Apr 25;43(1):125. doi: 10.1186/s13046-024-03042-7.
10
Frequencies of 4 tumor-infiltrating lymphocytes potently predict survival in glioblastoma, an immune desert.在免疫荒漠胶质母细胞瘤中，4 种肿瘤浸润淋巴细胞的频率能有力地预测生存。
Neuro Oncol. 2024 Mar 4;26(3):473-487. doi: 10.1093/neuonc/noad204.
Foxp3+ 调节性 T 细胞的表观遗传和转录控制。
Semin Immunol. 2015 Feb;27(1):10-8. doi: 10.1016/j.smim.2015.02.002. Epub 2015 Mar 20.
4
Treating recurrent glioblastoma: an update.复发性胶质母细胞瘤的治疗：最新进展
CNS Oncol. 2015;4(2):91-104. doi: 10.2217/cns.14.55.
5
Suppression of antigen presentation by IL-10.白细胞介素-10对抗抗原呈递的抑制作用。
Curr Opin Immunol. 2015 Jun;34:22-7. doi: 10.1016/j.coi.2014.12.009. Epub 2015 Jan 16.
6
Manipulating IL-10 signalling blockade for better immunotherapy.操控白细胞介素-10信号通路阻断以实现更好的免疫治疗。
Cell Immunol. 2015 Feb;293(2):126-9. doi: 10.1016/j.cellimm.2014.12.012. Epub 2015 Jan 8.
7
Glioma in 2014: unravelling tumour heterogeneity-implications for therapy.2014 年的神经胶质瘤：揭示肿瘤异质性——对治疗的启示。
Nat Rev Clin Oncol. 2015 Feb;12(2):69-70. doi: 10.1038/nrclinonc.2014.223. Epub 2015 Jan 6.
8
Proximity ligation assay evaluates IDH1R132H presentation in gliomas.邻近连接分析评估神经胶质瘤中异柠檬酸脱氢酶1（IDH1）R132H的表达情况。
J Clin Invest. 2015 Feb;125(2):593-606. doi: 10.1172/JCI77780. Epub 2015 Jan 2.
9
Glioblastoma multiforme - an overview.多形性胶质母细胞瘤——概述
Contemp Oncol (Pozn). 2014;18(5):307-12. doi: 10.5114/wo.2014.40559. Epub 2014 Aug 4.
10
Enhanced immunosuppression by therapy-exposed glioblastoma multiforme tumor cells.经治疗的多形性胶质母细胞瘤肿瘤细胞增强免疫抑制作用。
Int J Cancer. 2015 Jun 1;136(11):2566-78. doi: 10.1002/ijc.29309. Epub 2014 Nov 12.